{
  "id": 14962485,
  "title": "South Africa tightens rules on weight-loss drugs",
  "url": "https://urgent.news/2026/10/16/south-africa-tightens-rules-on-weight-loss-drugs",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-16T13:12:28.000Z",
  "source": {
    "name": "Semafor",
    "slug": "semafor",
    "url": "https://www.semafor.com/article/10/16/2026/south-africa-tightens-rules-on-weight-loss-drug-production"
  },
  "original_language": "en",
  "account": "South Africa is set to introduce stricter regulations governing the creation of homemade versions of certain medicines, including the widely used weight-loss and diabetes drugs Ozempic and Mounjaro, according to a Reuters report. This decision is anticipated to be favorable for major pharmaceutical companies, such as Novo Nordisk and Eli Lilly, as they strive to mitigate the competition posed by these pharmacy-manufactured alternatives to their lucrative GLP-1 medications.\n\nVincent Tlala, the CEO of the South African Pharmacy Council, revealed that his organization is collaborating with the industry regulator to revise the guidelines for compounding medicines, due to concerns that some pharmacies have transformed into \"small-scale manufacturers,\" producing substantial quantities of treatments in bulk rather than for individual patients. The proposed guidelines, expected to be released in March next year, come in the aftermath of a June court ruling in favor of Novo Nordisk, which successfully challenged local compounding pharmacies operating illegally by producing unauthorized copies of the drugs.\n\nWith the highest prevalence of adult obesity in Africa, South Africa has an obesity rate of 30%, rendering the drugs highly sought after within the country. However, the premium pricing of the trademarked version renders them inaccessible to the majority of the population.",
  "summary": "Pharmaceutical giants Novo Nordisk and Eli Lilly have sought to curb the pharmacy-made products competing with their blockbuster GLP-1 drugs.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}